DRAP to examine pleas against cancellation of hormone injections’ registration

Islamabad : The drug watchdog will examine the appeals against the cancellation of the registration of hormone injections later this week.

The Karachi-based Ghazi Brothers had challenged the decision of the Drug Regulatory Authority of Pakistan's Central Registration Board to cancel the registration of Boostin-S injection (Registration No. 069645) and Boostin-250 injection (Registration No. 020819) with the authority's Appellate Board.

Now, the Appellate Board will take them up in its 149th meeting on January 26 (Friday).

The appellant will send a representative to the meeting to plead its case. However, its failure to do so, ex-parte decision will be made on the plea.

The DRAP Appellate Board is tasked with hearing appeals against the decisions of the authority's Central Licensing Board, Registration Board or Pricing Committee.

Also, January 26th meeting will consider the appeal of the Marion Laboratories (Private) Limited, Karachi, against refusal of the Central Licensing Board to renew its drug manufacturing licence and that of the Ankaz Pharmex (Private) Limited, Karachi, against the cancellation of its drug manufacturing licence by the Central Licensing Board.

DRAP chief executive officer Dr Mohammad Aslam will chair the meeting, where all provincial secretaries will be in attendance as board members besides the relevant officials and the representatives of the appellants.